newsfilter
← Latest News
GlobeNewswire·

Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates

Product sales from Olverembatinib in the first half of 2025 increased 93% year-over-year to US$30.3 million (RMB217.4 million), primarily attributable to the expansion of NRDL coverageCommenced commercial sales of